You’ve done significant work on lung cancer in non-smokers. What are we learning about why these cancers develop?
Lung cancer in never smokers is an increasing problem. In smokers, we pretty much understand that tobacco contains a number of carcinogens that have an important role in direct carcinogenesis through direct mutagenesis, which results in malignancy developing. The biological processes that result in lung cancer in never smokers has never been very clear. We see different types of lung cancer and never smokers, the archetypal common type being EGFR mutant lung cancer. So why is it that this happens?
At The Royal Marsden’s, we have done a lot of work in how these patients can get treated optimally. My colleague, Charlie Swanton, at the Crick Institute, London, UK, has really revolutionised our understanding of how these cancers actually develop. He proposed a two-step model for lung cancer in never smokers: something called an initiation step, and something called a promoter step. In the initiation step, he did some work which identified that at a very low level in patients who ultimately develop lung cancer as never smokers, these patients will have genetic abnormalities in their normal airway cells, such as an EGFR mutation, but not all of those patients go on to develop lung cancer. So, what is it? Why is it that those patients then develop lung cancer? Swanton did some beautiful work, both epidemiologically and in the lab, with colleagues demonstrating that inhaled toxins, such as particle matter 2.5 particles, alongside tumour infiltrating macrophages with clonal hemopoiesis of uncertain malignant potential can act as promoters in that milieu to really select out those cells already with initiated EGFR event. Through the additional function and interaction with macrophages, this then causes inflammation through secretion of IL-1β to result in expansion of the EGFR mutant cell chain.
For the first time, this explains why patients who have an EGFR mutation may or may not develop lung cancer. It explains why we see EGFR mutant lung cancers in areas of increased pollution and explains the interplay between pollution, macrophages, cells with chip, and the overrepresentation of IL-1β within that inflammatory microenvironment to result in lung cancer developing. This is a wonderful new hypothesis which puts it all together.
You helped lead the NHS England programme that brought circulating tumour DNA (ctDNA) testing into lung cancer care. Can you talk us through what the programme involved and why was it so important to pursue?
Lung cancer is a disease that presents usually at advanced stage, where patients are really unwell, and making an effective diagnosis is critical. But more than that, these days we now need to do comprehensive molecular profiling on the actual sample to demonstrate that we know what the molecular genotype of the tumour is and that way we can give the patient the right treatment. For example, if the patient has oncogene addicted lung cancer we can give them the appropriate targeted kinase inhibitor therapy for their cancer. And if they don’t, then they usually need an immune checkpoint inhibitor-based strategy.
As the whole diagnostic process can take a long time, we actually identified that nearly 80–90% of patients need to be treated within 62 days of presenting, but what we’re finding in reality is that only about 50% of patients meet that metric. How can we improve that whole diagnostic journey to get patients on the right strategy?
Initially, what we did is paired work with tissue and ctDNA genotyping to show that both are complementary, both have difficulties in genotyping, and both are effective ways of genotyping as well. If you implement ctDNA, you can reduce the time to treatment by around a half, which is really important for getting patients through the whole diagnostic journey. A group of us had discussions with NHS England, and they agreed that this is something that can really help get our patients on the correct treatment much quicker.
We implemented a phased implementation of ctDNA. In Phase 1, we tested a small number of patients at presentation in the respiratory clinic with ctDNA up front alongside the standard journey. We demonstrated it’s feasible to do this, and anecdotally, we were hearing that we were getting patients on targeted treatment far quicker, exactly as we would expect to from our original data. That was done using two commercial ctDNA tests, but at that time, we already had our Marsden laboratory implementing the Marsden 360 test: a test developed by our partner Guardant Health, who are leading industry pioneers in liquid biopsy testing. We then moved to Phase 2, where we implemented ctDNA in a larger number of patients nationally using the Marsden 360 test, keeping the test in the UK rather than shipping it out commercially.
Alongside this, we implemented a health technology appraisal test to really evaluate the cost effectiveness of doing the ctDNA test. We then smoothly moved that into Phase 3, where we implemented that in a large number of patients up and down the country, between January 2023–April 2024. Our health economic evaluation identified that ctDNA was economically viangsble if you’re then not needing to do tissue next-generation sequencing (NGS), which you won’t need to do if you already have the result with ctDNA. Additionally, it identifies people suitable for targeted treatment and not targeted treatment, and it gets them through the treatment plan quicker, and you get patients on the correct treatment more effectively.
So, it is economically viable, and as a consequence of that, as of April 2025, England is the only country globally where the government have funded ctDNA NGS sequencing for all patients with suspected advanced lung cancer presenting to the respiratory clinic and in the emergency room, or if tissue NGS is found.
As Chair of the European Society of Medical Oncology (ESMO) Guidelines Committee, how do you decide when new evidence is strong enough to change clinical guidelines?
Guidelines are really critical for ensuring we have high-quality care for our patients in the clinic because, whilst I might be an expert, in another country or centre, the oncologist treating the patient may not be an expert and would need access to high-quality guidelines.
Of course, ESMO have a standard operating procedure for how guidelines work and that is freely available in the public domain. You can download it from the asthma clinical guidelines website. But what it will say is that ideally to go into a guideline, you need an approved therapy, treatment, or recommendation that has already gone through a regulator. However, we may accept treatments which don’t have regulatory approval, which we are allowed to put in the guidelines if we have robust evidence; if, for example, there is imminent approval and there is a published publication in a peer-reviewed journal.
Our guidelines have two marks by them, demonstrating to the reader what level of evidence that guideline has, the statement of treatment intent, and what grade of recommendation it is. This is because some sentences state what we think you should be able to do, but may not have a strong rate of recommendation compared to others which we very strongly recommend. So, when you read the guidelines, always look at the recommendation, look at the level of evidence, and look at the grade of recommendation, but recognise that by and large, these are approved recommendations or recommendations which are imminently going to be approved.
With new evidence and treatments emerging so quickly in oncology, how do you ensure guidelines remain up to date without moving faster than the evidence allows?
The guidelines are kept up to date because we have processes for updating them. Not only do we have a full revamp of the entire clinical practice guidelines, but sometimes we have what are called ‘living guidelines’ where for hot topics or common disease areas, the lead authors of the guidelines will ensure they are kept up to date with the most important information. Sometimes the changes are even more subtle, and you don’t need a living guideline update. These are called express updates. So, we have mechanisms in place whereby sometimes we have a full guideline change, sometimes we have a living guideline update, and sometimes we have an express update. Always check the website, as that’s where it’s kept live.
With the congress approaching, are there any particular sessions or developments you think attendees should prioritise?
Go to as much as you can, because it’s a festival of new data. Within the program we have an educational track, a nursing track, and a scientific track.
The educational track gives you oversight by some of the world’s top experts on key areas of uncertainty and multidisciplinary work on how we should be approaching certainty. Our scientific track is where we’re presenting new data, and as our program is not quite finalised, there are many late-breaking abstracts which we are yet to decide about. Looking at the pace of oncology change and looking at the number of press releases that have been put in the public domain in recent months, I predict that this will be a really exciting event.
I’m predicting several practice changing presentations will be presented, so always keep an eye out on the presidential sessions, which we try to ensure we have the best practice changing data presented in. I think it’s going to be an amazing meeting.
With so many new treatments emerging, what are the biggest challenges in getting promising discoveries from the laboratory into the NHS?
There’s a long way between a laboratory finding and routine care. We have to design and run clinical trials and ensure they are run to a regulatory standard. We must make sure that we are successfully running our trials. There’s no point opening a trial if you can’t recruit to it, so we’ve got to make sure that if we open a trial we have to recruit to that trial to the best of our ability.
After you do that, you have to make sure that your country’s regulator, such as the Medicines & Healthcare products Regulatory Agency (MHRA) for the UK, sees that there is a benefit for this. Then you work with the company or the regulator, if needed, to get the drug through the regulatory process.
We’re seeing quicker approvals these days, so I think we’re in a good place for a regulatory environment. One of the other barriers thereafter is reimbursement, and I think all European countries have this challenge because the drug needs to go undergo a reimbursement step after regulatory approval.
We need to ensure that we work with our industry partners to ensure that whatever we find in the lab makes its way through to registrational trials through the regulator, but above all, through the reimbursement agencies so that our patients can benefit.
Looking ahead, what is the next major breakthrough in lung cancer treatment that you think we could realistically see?
One area which is super exciting that has really kicked off after many decades of having little, if any, change is small cell lung cancer. We are now starting to reap the rewards of T cell engagers and antibody drug conjugates.
We had a press release recently about the DELFI-305 trial summarising that tarlatamab in addition to chemotherapy with immunotherapy improves survival over standard chemo immunotherapy. I think that will be a paradigm shift in how we manage our first-line patients with extensive stage small cell lung cancer, and perhaps one of the biggest changes in a generation for this disease. Hopefully it will show that patients derive long-term benefits, because it’s not straightforward to deliver this type of treatment to our first-line patients who can often be quite sick.
At the World Lung Cancer Conference, we had two large data sets of relapse small cell lung cancer demonstrating that a topoisomerase I payload antibody drug conjugate versus topoisomerase II both improved overall survival.
These are inevitably going to be brought into the first line setting as well. It’s going to be a very exciting time for drug development in extensive stage small cell lung cancer. Whatever happens in that, we’re going to head out into limited stage small cell lung cancer as well.
Our non-small cell lung cancer area is also very active with drug development. At the World Lung Cancer meeting, we heard the very weighted data from HARMONi 2, where we were shown that there’s an overall survival advantage for ivonesimab over pembrolizumab. We’ve been struggling to beat pembrolizumab for many years in lung cancer and many companies have vascular endothelial growth factor (VEGF), programmed cell death protein-1 (PD-1), and programmed death-ligand 1 (PD-L1) bispecifics in development.
I think it’s going to be a very exciting area in non-oncogene addicted lung cancer for quite a period of time, and there are multiple new targeted agents coming through for oncogene addicted lung cancer.





